Hepatitis C - MIGENIX Initiates Enrollment in Phase IIb Hepatitis C Clinical Study of Celgosivir

MIGENIX Initiates Enrollment in Phase IIb Hepatitis C Clinical Study of Celgosivir
BC Technology - glucosidase 1 inhibitor, in development for the treatment of chronic hepatitis C virus infections the success of treatment for patients suffering from chronic hepatitis C infections

Biolex Therapeutics begins trial of hepatitis C drug
Pharmaceutical Business Review - Biolex Therapeutics has revealed that the first cohort of subjects in the company's phase I study of investigational hepatitis C candidate, Locteron, have been dosed. initially for the treatment of patients with chronic hepatitis C. Locteron combines BLX-883, a recombinant under development for the treatment of patients with chronic hepatitis C.